BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10764312)

  • 1. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
    Niewoehner DE; Collins D; Erbland ML
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1201-5. PubMed ID: 10764312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
    Niewoehner DE; Erbland ML; Deupree RH; Collins D; Gross NJ; Light RW; Anderson P; Morgan NA
    N Engl J Med; 1999 Jun; 340(25):1941-7. PubMed ID: 10379017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): rationale and design of an equivalence trial. Veterans Administration Cooperative Trials SCCOPE Study Group.
    Erbland ML; Deupree RH; Niewoehner DE
    Control Clin Trials; 1998 Aug; 19(4):404-17. PubMed ID: 9683314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
    N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
    Qaseem A; Wilt TJ; Weinberger SE; Hanania NA; Criner G; van der Molen T; Marciniuk DD; Denberg T; Schünemann H; Wedzicha W; MacDonald R; Shekelle P; ; ; ;
    Ann Intern Med; 2011 Aug; 155(3):179-91. PubMed ID: 21810710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
    Lee TA; Schumock GT; Bartle B; Pickard AS
    Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.
    Dummer JF; Epton MJ; Cowan JO; Cook JM; Condliffe R; Landhuis CE; Smith AD; Taylor DR
    Am J Respir Crit Care Med; 2009 Nov; 180(9):846-52. PubMed ID: 19661244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.
    Casanova C; de Torres JP; Aguirre-Jaíme A; Pinto-Plata V; Marin JM; Cordoba E; Baz R; Cote C; Celli BR
    Am J Respir Crit Care Med; 2011 Nov; 184(9):1015-21. PubMed ID: 21836135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute exacerbation of COPD: factors associated with poor treatment outcome.
    Dewan NA; Rafique S; Kanwar B; Satpathy H; Ryschon K; Tillotson GS; Niederman MS
    Chest; 2000 Mar; 117(3):662-71. PubMed ID: 10712989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
    Yetkin O; Gunen H
    Clin Respir J; 2008 Jan; 2(1):36-40. PubMed ID: 20298302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and risk factors of airflow obstruction in an elderly Chinese population.
    Ko FW; Woo J; Tam W; Lai CK; Ngai J; Kwok T; Hui DS
    Eur Respir J; 2008 Dec; 32(6):1472-8. PubMed ID: 18684847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hospital admission for chronic obstructive pulmonary disease exacerbations in Canadian emergency departments.
    Rowe BH; Villa-Roel C; Guttman A; Ross S; Mackey D; Sivilotti ML; Worster A; Stiell IG; Willis V; Borgundvaag B
    Acad Emerg Med; 2009 Apr; 16(4):316-24. PubMed ID: 19298621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
    Soler N; Agustí C; Angrill J; Puig De la Bellacasa J; Torres A
    Thorax; 2007 Jan; 62(1):29-35. PubMed ID: 16928715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease.
    Wilkinson TM; Donaldson GC; Hurst JR; Seemungal TA; Wedzicha JA
    Am J Respir Crit Care Med; 2004 Jun; 169(12):1298-303. PubMed ID: 14990395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.